Workflow
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
Alto NeuroscienceAlto Neuroscience(US:ANRO) Businesswire·2025-10-03 11:34

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #FastTrack--Alto Neuroscience, Inc. ("Alto†) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophr ...